Core Laboratories Inc. $CLB Shares Sold by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. has reduced its ownership in Core Laboratories Inc. by 28.6%, now holding 152,043 shares valued at approximately $2.28 million as of the latest SEC filing.
• Core Laboratories reported earnings per share of $0.19 for the last quarter, surpassing analyst expectations, although revenue showed a slight decline of 0.3% year-over-year.
• The company announced a quarterly dividend of $0.01 per share, with a 0.4% yield, reflecting a payout ratio of 6.45%.

Russell Investments Group Ltd. decreased its position in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 28.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 152,043 shares of the oil and gas company's stock after selling 60,780 shares during the period. Russell Investments Group Ltd. owned 0.32% of Core Laboratories worth $2,279,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in CLB. Barclays PLC increased its position in Core Laboratories by 3.3% during the fourth quarter. Barclays PLC now owns 86,300 shares of the oil and gas company's stock worth $1,494,000 after buying an additional 2,730 shares during the period. First Trust Advisors LP acquired a new position in Core Laboratories during the fourth quarter worth approximately $606,000. Dimensional Fund Advisors LP increased its position in Core Laboratories by 3.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 847,983 shares of the oil and gas company's stock worth $14,678,000 after buying an additional 28,393 shares during the period. MetLife Investment Management LLC increased its holdings in shares of Core Laboratories by 8.8% in the fourth quarter. MetLife Investment Management LLC now owns 29,594 shares of the oil and gas company's stock valued at $512,000 after purchasing an additional 2,388 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Core Laboratories by 843.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock valued at $57,000 after purchasing an additional 2,936 shares during the period. Institutional investors and hedge funds own 97.81% of the company's stock.

Core Laboratories Trading Down 0.7%

Shares of CLB stock opened at $11.0970 on Tuesday. The business's fifty day moving average price is $11.55 and its 200 day moving average price is $12.69. Core Laboratories Inc. has a 1-year low of $9.72 and a 1-year high of $21.83. The firm has a market capitalization of $520.34 million, a PE ratio of 17.90, a P/E/G ratio of 3.37 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.27 and a quick ratio of 1.70.

Core Laboratories (NYSE:CLB - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The oil and gas company reported $0.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.01. The firm had revenue of $130.16 million for the quarter, compared to analyst estimates of $129.19 million. Core Laboratories had a return on equity of 14.15% and a net margin of 5.73%.Core Laboratories's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.22 earnings per share. Core Laboratories has set its Q3 2025 guidance at 0.180-0.220 EPS. As a group, sell-side analysts forecast that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.

Core Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 25th. Shareholders of record on Monday, August 4th were given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Monday, August 4th. Core Laboratories's payout ratio is presently 6.45%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Zacks Research raised Core Laboratories from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Citigroup dropped their price objective on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, Stifel Nicolaus dropped their price objective on Core Laboratories from $13.00 to $12.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $12.50.

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories Inc. (NYSE:CLB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.